Welcome to our dedicated page for CEL SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CEL SCI's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CEL SCI's regulatory disclosures and financial reporting.
CEL-SCI Corporation has signed a strategic partnership with Amarox to register, commercialize, and distribute its investigational cancer immunotherapy Multikine for head and neck cancer in Saudi Arabia, with an option to expand into Gulf Cooperation Council countries.
Amarox will lead all Saudi Food and Drug Authority regulatory activities, including seeking Breakthrough Medicine Designation, and will become the exclusive distributor in Saudi Arabia if SFDA approval is granted. Net revenue from Multikine sales in Saudi Arabia will be shared equally on a 50%/50% basis, while CEL-SCI keeps global intellectual property and manufacturing rights. The deal targets a fast-growing Saudi cancer immunotherapy market projected to reach $2.7 billion by 2033 and aligns with Saudi Arabia’s Vision 2030 health initiatives.
CEL SCI CORP director and Chief Executive Officer Geert R. Kersten reported buying additional company shares. On May 13, 2026, he purchased 100,000 shares of restricted common stock directly from the company at $1.19 per share, equal to the May 12, 2026 closing price. Following this transaction, his direct holdings increased to 222,497 common shares, indicating a substantial expansion of his personal equity stake.
CEL-SCI Corporation priced a best-efforts public offering of 6,000,000 shares of common stock at $1.20 per share, for expected gross proceeds of about $7.2 million before fees and expenses. The offering is expected to close on May 13, 2026, subject to customary closing conditions.
The company plans to use the cash to continue developing its investigational cancer immunotherapy Multikine, as well as for general corporate purposes and working capital. Multikine has been dosed in over 740 patients and has received FDA Orphan Drug designation for neoadjuvant treatment of head and neck cancer, but it is not yet approved for sale.
CEL-SCI Corporation is offering 6,000,000 shares of its common stock at $1.20 per share on a best-efforts basis. The company expects net proceeds of approximately $6.5M to fund continued development of Multikine and for general corporate purposes. There is no minimum offering amount, the placement agent will use reasonable best efforts to arrange sales, and delivery is expected on or about May 13, 2026.
The prospectus states 8,493,111 shares were outstanding as of May 11, 2026, and assumes no exercise of 710,491 options or 36,421 warrants noted in the filing. The offering is structured so proceeds will be available for immediate use by the company upon receipt.
CEL-SCI Corporation is registering up to 4,885,993 shares of common stock, Pre-Funded Warrants to purchase up to 4,885,993 shares, and 4,885,993 underlying shares in a primary, best efforts offering. The assumed price is $3.07 per share, with estimated net proceeds of about $13.7 million.
The company plans to use the funds mainly to advance its lead cancer immunotherapy Multikine, including a planned 212‑patient confirmatory Phase III study, and for general corporate purposes. Common shares outstanding would rise from 8,492,777 to 13,378,770 if all shares are sold and no Pre‑Funded Warrants are issued, meaning substantial dilution to new investors.
CEL‑SCI is a late clinical‑stage biotech focused on immunotherapies for head and neck cancer and rheumatoid arthritis. Recent financials show significant operating and net losses, going‑concern uncertainty, and material weaknesses in internal controls, underscoring its dependence on raising capital and obtaining regulatory approval for Multikine.
CEL-SCI Corporation is registering up to 3,440,367 shares of common stock, together with up to 3,440,367 pre-funded warrants and 3,440,367 underlying shares, in a best efforts primary offering. The assumed price is $4.36 per share, targeting approximately $13.7 million in net proceeds.
The company plans to use the cash mainly to fund development of its lead cancer immunotherapy Multikine and for general corporate purposes. CEL-SCI reports ongoing operating losses, including a $25.4 million net loss in fiscal 2025, has raised substantial doubt about its ability to continue as a going concern, and warns of significant dilution and risk given there is no minimum offering amount.
CEL SCI CORP Chief Scientific Officer Talor Eyal reported an acquisition of 747 shares of Common Stock on 2026-03-31. The shares were characterized as a grant, award, or other acquisition at a reported value of $3.21 per share. Following this transaction, Eyal directly holds 7,011 shares of CEL SCI CORP common stock.
PRICHEP PATRICIA B reported acquisition or exercise transactions in this Form 4 filing.
CEL-SCI Corp Chief Financial Officer Patricia B. Prichep received a grant of 1,336 shares of Common Stock on March 31, 2026. The grant is recorded at $3.21 per share and brings her direct holdings to 13,364 shares, reflecting a routine compensation-related equity award.
KERSTEN GEERT R reported acquisition or exercise transactions in this Form 4 filing.
CEL SCI CORP reported that Chief Executive Officer Geert R. Kersten received a stock grant of 1,682 shares of common stock on March 31, 2026. The grant was valued at $3.21 per share. Following this award, he directly holds 122,497 common shares.